Publications

Add filters (0)

8 results

Objective and noninvasive biochemical markers in rheumatoid arthritis: where are we and where are we going?

March 1, 2021

Expert Rev Proteomics

Abstract INTRODUCTION Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects approximately 1% of the adult population. RA is multi-factorial, and as such our understanding of the molecular pathways involved in the disease is currently limited. An increasing number of studies have suggested that several molecular phenotypes (i.e. endotypes) of RA exist, and that […]

Read publication

Improvement of non-invasive markers of NAFLD from an individualised, web-based exercise program.

October 1, 2019

Aliment Pharmacol Ther

Abstract BACKGROUND Lifestyle modifications remain the cornerstone of treatment in non-alcoholic fatty liver disease (NAFLD). However, they requently fail related to the inability of patients to implement lasting changes. AIMS To evaluate the effects of a short, web-based, individualised exercise program on non-invasive markers of hepatic steatosis, inflammation and fibrosis. METHODS Patients with histologically confirmed […]

Read publication

Recent advances in understanding the phenotypes of osteoarthritis.

January 1, 2019

F1000Res

Abstract Recent research in the field of osteoarthritis (OA) has focused on understanding the underlying molecular and clinical phenotypes of the disease. This narrative review article focuses on recent advances in our understanding of the phenotypes of OA and proposes that the disease represents a diversity of clinical phenotypes that are underpinned by a number […]

Read publication

Quantification of altered tissue turnover in a liquid biopsy: a proposed precision medicine tool to assess chronic inflammation and desmoplasia associated with a pro-cancerous niche and response to immuno-therapeutic anti-tumor modalities.

January 1, 2018

Cancer Immunol Immunother

Abstract Immuno-therapy has begun to revolutionize cancer treatment. However, despite the significant progress achieved in regard to the duration of clinical benefits, a substantial number of patients do not respond to these therapies. To improve the outcome of patients receiving immuno-therapy, there is a need for novel biomarkers that can predict and monitor treatment. Tumor […]

Read publication

Inflammation (or synovitis)-driven osteoarthritis: an opportunity for personalizing prognosis and treatment?

January 1, 2016

Scand J Rheumatol

Abstract The disabling and painful disease osteoarthritis (OA) is the most common form of arthritis. Strong evidence suggests that a subpopulation of OA patients has a form of OA driven by inflammation. Consequently, understanding when inflammation is the driver of disease progression and which OA patients might benefit from anti-inflammatory treatment is a topic of […]

Read publication

Clinical Drug Development Using Dynamic Biomarkers to Enable Personalized Health Care in COPD.

July 1, 2015

Chest

Abstract Despite massive investments in the development of novel treatments for heterogeneous diseases such as COPD, the resources spent have only benefited a fraction of the population treated. Personalized health care to guide selection of a suitable patient population already in the clinical development of new compounds could offer a solution. This review discusses past […]

Read publication

Osteoarthritis–a case for personalized health care?

January 1, 2014

Osteoarthritis Cartilage

Abstract For both economic and ethical reasons, identification of the optimal treatment for each individual patient is a pressing concern, not only for the patients and their physician, but also health care payers and the pharmaceutical industry. In the field of osteoarthritis (OA) this is of particular relevance, due to the heterogeneity of the disease […]

Read publication